Cellectar Biosciences
CLRB
10 hedge funds and large institutions have $2.92M invested in Cellectar Biosciences in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0.01% less ownership
Funds ownership: 0.05% → 0.05% (-0.01%)
3% less capital invested
Capital invested by funds: $3.01M → $2.92M (-$89.1K)
17% less funds holding
Funds holding: 12 → 10 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$38K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$17.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$471K |
| 2 |
Morgan Stanley
New York
|
-$34.3K |
| 3 |
JP Morgan Chase
New York
|
-$21K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$20K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$8.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Boxer Capital
San Diego,
California
| $2.07M | – | – | – |
|
|
2
Renaissance Technologies
New York
| $448K | +$38K | +73 | +12% |
|
|
SFM
3
Sphera Funds Management
Tel Aviv,
Israel
| $197K | – | – | – |
|
|
GPFA
4
Game Plan Financial Advisors
Westlake,
Ohio
| $98K | +$75.4K | +145 | New |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $38K | – | – | – |
|
|
6
Morgan Stanley
New York
| $27K | -$34.3K | -66 | -62% |
|
|
7
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $23K | +$17.2K | +33 | New |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $10K | -$8.84K | -17 | -57% |
|
9
US Bancorp
Minneapolis,
Minnesota
| $6K | – | – | – |
|
|
TCM
10
Tang Capital Management
San Diego,
California
| – | -$471K | -786 | Closed |
|
|
PAG
11
Private Advisor Group
Morristown,
New Jersey
| – | -$20K | -45 | Closed |
|
|
12
JP Morgan Chase
New York
| – | -$21K | -35 | Closed |
|
13
Victory Capital Management
San Antonio,
Texas
| – | -$3K | -4 | Closed |
|
|
KFS
14
Kelly Financial Services
Braintree,
Massachusetts
| – | -$54 | – | – |
|
CLRB Hedge Fund Activity: Q4 2019 in Review
10 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2019, worth a combined $2.92M — down 3% from $3.01M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLRB and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $38K. The largest seller was Tang Capital Management, exiting entirely with an estimated $471K sold.
- 10 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2019, down from 12 in Q3 2019.
- Funds reported $2.92M of Cellectar Biosciences stock for Q4 2019, down 3% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q4 2019 and 4 closed out, a net change of -2 holders.
- The largest Cellectar Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $38K added.
- The largest Cellectar Biosciences seller in Q4 2019 was Tang Capital Management, an estimated $471K sold.
Based on aggregated 13F filings for Q4 2019.